Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down – Here’s What Happened

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG)’s share price gapped down prior to trading on Friday . The stock had previously closed at $24.05, but opened at $21.00. Ascentage Pharma Group International shares last traded at $20.5350, with a volume of 3,134 shares changing hands.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on AAPG shares. Truist Financial set a $51.00 price target on shares of Ascentage Pharma Group International in a research note on Monday, November 24th. Lucid Cap Mkts upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, December 15th. Rodman & Renshaw started coverage on Ascentage Pharma Group International in a report on Tuesday, January 13th. They set a “buy” rating and a $48.00 price objective on the stock. BTIG Research started coverage on Ascentage Pharma Group International in a research report on Thursday, March 12th. They set a “buy” rating and a $48.00 target price on the stock. Finally, Oppenheimer started coverage on Ascentage Pharma Group International in a report on Thursday, December 4th. They issued an “outperform” rating and a $45.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating and five have assigned a Buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $48.00.

Ascentage Pharma Group International Trading Down 13.3%

The company has a quick ratio of 1.53, a current ratio of 1.54 and a debt-to-equity ratio of 1.31. The firm has a 50 day simple moving average of $24.57 and a two-hundred day simple moving average of $30.43.

Institutional Trading of Ascentage Pharma Group International

Hedge funds have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Ascentage Pharma Group International during the third quarter worth about $96,000. ABC Arbitrage SA acquired a new stake in Ascentage Pharma Group International in the third quarter valued at about $204,000. Citadel Advisors LLC purchased a new stake in Ascentage Pharma Group International in the 3rd quarter valued at approximately $383,000. Hsbc Holdings PLC acquired a new position in Ascentage Pharma Group International during the 2nd quarter worth approximately $391,000. Finally, UBS Group AG increased its position in Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after purchasing an additional 10,988 shares during the period.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.